Full Text Sources
Red bone marrow (RM) is often the primary organ at risk in radioimmunotherapy; irradiation of marrow may induce short and long term hematological toxicity. (177)Lu-lilotomab satetraxetan is a novel anti-CD37 antibody-radionuclide-conjugate (ARC) currently in phase 1/2a. Two pre-dosing regimens have been investigated, one with 40 mg unlabeled lilotomab antibody (arm 1) and one without (arm 2). The aim of this work was to compare RM absorbed doses for the two arms and to correlate absorbed doses with hematological toxicity.
PMID: 27587710 [PubMed - as supplied by publisher]